90 related articles for article (PubMed ID: 23358197)
21. Diagnostic criteria and treatment of Buerger's disease: a review.
Lazarides MK; Georgiadis GS; Papas TT; Nikolopoulos ES
Int J Low Extrem Wounds; 2006 Jun; 5(2):89-95. PubMed ID: 16698911
[TBL] [Abstract][Full Text] [Related]
22. [Aspects of thrombophilia in Buerger's disease].
Caramaschi P; Biasi D; Volpe A; Carletto A; Bambara LM
Recenti Prog Med; 2000 Sep; 91(9):436-40. PubMed ID: 11021165
[TBL] [Abstract][Full Text] [Related]
23. Plasma catecholamines in Buerger's disease: effects of cigarette smoking and surgical sympathectomy.
Roncon-Albuquerque R; Serrão P; Vale-Pereira R; Costa-Lima J; Roncon-Albuquerque R
Eur J Vasc Endovasc Surg; 2002 Oct; 24(4):338-43. PubMed ID: 12323177
[TBL] [Abstract][Full Text] [Related]
24. [Dynamic changes in plasma levels of urokinase type plasminogen activator and urokinase type plasminogen activator receptor in patients with systemic inflammatory response syndrome].
Wu XL; Yu L; Long D; Yang JH; Zhang YC; Geng F
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2011 Aug; 23(8):478-81. PubMed ID: 21878172
[TBL] [Abstract][Full Text] [Related]
25. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
Idell S
Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
[TBL] [Abstract][Full Text] [Related]
26. Thromboangiitis obliterans. An update on Buerger's disease.
Szuba A; Cooke JP
West J Med; 1998 Apr; 168(4):255-60. PubMed ID: 9584663
[TBL] [Abstract][Full Text] [Related]
27. Circulating angiogenic factors in patients with thromboangiitis obliterans.
Hewing B; Stangl V; Stangl K; Enke-Melzer K; Baumann G; Ludwig A
PLoS One; 2012; 7(4):e34717. PubMed ID: 22506045
[TBL] [Abstract][Full Text] [Related]
28. [Buerger's disease].
Chochola M; Márová K; Linhart A
Cas Lek Cesk; 2006; 145(5):358-62. PubMed ID: 16755770
[TBL] [Abstract][Full Text] [Related]
29. Increased Serum HMGB-1, ICAM-1 and Metalloproteinase-9 Levels in Buerger's Patients.
De Caridi G; Bitto A; Massara M; Pallio G; Pizzino G; Serra R; Altavilla D; Squadrito F; Spinelli F
Curr Vasc Pharmacol; 2016; 14(4):382-7. PubMed ID: 26935815
[TBL] [Abstract][Full Text] [Related]
30. High intakes of trans monounsaturated fatty acids taken for 2 weeks do not influence procoagulant and fibrinolytic risk markers for CHD in young healthy men.
Sanders TA; Oakley FR; Crook D; Cooper JA; Miller GJ
Br J Nutr; 2003 Jun; 89(6):767-76. PubMed ID: 12828793
[TBL] [Abstract][Full Text] [Related]
31. Penile and scrotal involvement in Buerger's disease.
Aktoz T; Kaplan M; Yalcin O; Atakan IH; Inci O
Andrologia; 2008 Dec; 40(6):401-3. PubMed ID: 19032693
[TBL] [Abstract][Full Text] [Related]
32. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger's disease).
Makita S; Nakamura M; Murakami H; Komoda K; Kawazoe K; Hiramori K
Circulation; 1996 Nov; 94(9 Suppl):II211-5. PubMed ID: 8901748
[TBL] [Abstract][Full Text] [Related]
33. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
34. Response to DDAVP stimulation in thirteen patients with Buerger's disease.
Siguret V; Alhenc-Gelas M; Aiach M; Fiessinger JN; Gaussem P
Thromb Res; 1997 Apr; 86(1):85-7. PubMed ID: 9172291
[No Abstract] [Full Text] [Related]
35. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Ho CH; Yuan CC; Liu SM
Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
[TBL] [Abstract][Full Text] [Related]
36. G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buerger's disease) and their removal by immunoadsorption.
Klein-Weigel PF; Bimmler M; Hempel P; Schöpp S; Dreusicke S; Valerius J; Bohlen A; Boehnlein JM; Bestler D; Funk S; Elitok S
Vasa; 2014 Sep; 43(5):347-52. PubMed ID: 25147011
[TBL] [Abstract][Full Text] [Related]
37. [Anticardiolipin antibodies in patients with Buerger's disease].
Cnotliwy M; Gutowski P; Szumiłowicz H; Kucharska E; Jastrzebska M; Ostanek L
Wiad Lek; 1999; 52(7-8):332-6. PubMed ID: 10540577
[TBL] [Abstract][Full Text] [Related]
38. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications.
Erem C; Hacihasanoğlu A; Celik S; Ovali E; Ersöz HO; Ukinç K; Deger O; Telatar M
Med Princ Pract; 2005; 14(1):22-30. PubMed ID: 15608477
[TBL] [Abstract][Full Text] [Related]
39. Clinical and morphological aspects of Buerger's disease.
Majewski W; Marszalek A; Staniszewiski R; Majewski P; Zapalski S; Biczysko W
Int Angiol; 1997 Dec; 16(4):239-44. PubMed ID: 9543220
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation of hemodynamic changes in Buerger's disease patients].
Vicente I; Alves A; Pereira A; Roncon de Albuquerque R
Acta Med Port; 2012; 25(3):156-64. PubMed ID: 23069235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
